Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10945315,oral clearances,"In subjects in the extensive metabolizer group, coadministration of propafenone decreased oral clearances of R-(-)-mexiletine (from 41+/-11 L/h to 28+/-7 L/h) and S-(+)-mexiletine (from 43+/-15 L/h to 29+/-11 L/h) to an extent such that these values were no longer different between the extensive and the poor metabolizer groups.",Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945315/),[l] / [h],41,6655,DB00379,Mexiletine
,10945315,oral clearances,"In subjects in the extensive metabolizer group, coadministration of propafenone decreased oral clearances of R-(-)-mexiletine (from 41+/-11 L/h to 28+/-7 L/h) and S-(+)-mexiletine (from 43+/-15 L/h to 29+/-11 L/h) to an extent such that these values were no longer different between the extensive and the poor metabolizer groups.",Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945315/),[l] / [h],28,6656,DB00379,Mexiletine
,10945315,oral clearances,"In subjects in the extensive metabolizer group, coadministration of propafenone decreased oral clearances of R-(-)-mexiletine (from 41+/-11 L/h to 28+/-7 L/h) and S-(+)-mexiletine (from 43+/-15 L/h to 29+/-11 L/h) to an extent such that these values were no longer different between the extensive and the poor metabolizer groups.",Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945315/),[l] / [h],43,6657,DB00379,Mexiletine
,10945315,oral clearances,"In subjects in the extensive metabolizer group, coadministration of propafenone decreased oral clearances of R-(-)-mexiletine (from 41+/-11 L/h to 28+/-7 L/h) and S-(+)-mexiletine (from 43+/-15 L/h to 29+/-11 L/h) to an extent such that these values were no longer different between the extensive and the poor metabolizer groups.",Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945315/),[l] / [h],29,6658,DB00379,Mexiletine
,6326558,systemic bioavailability,"Uptake and distribution of mexiletine are rapid, systemic bioavailability is about 90%, and tissue distribution is extensive.","Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326558/),%,90,12552,DB00379,Mexiletine
,6326558,Elimination half-life,Elimination half-life is 9 to 11 hours after intravenous or oral administration.,"Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326558/),h,9 to 11,12553,DB00379,Mexiletine
greater,9435098,recoveries,Plasma samples (500 microliters) showed recoveries greater than 75% for both the metabolites.,Enantioselective determination of the hydroxylated metabolites of mexiletine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435098/),%,75,15172,DB00379,Mexiletine
,32249350,concentrations,"The predicted flecainide concentrations after multiple flecainide doses (50 mg BID) in the anuric hemodialysis with cirrhosis population were comparable with the observed value (3602 ng/mL), which fell between the predicted concentrations in the absence and presence of mexiletine (3043 [718-8499] and 5914 [880-20,624] ng/mL, respectively).",Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32249350/),[ng] / [ml],3043,16636,DB00379,Mexiletine
,32249350,concentrations,"The predicted flecainide concentrations after multiple flecainide doses (50 mg BID) in the anuric hemodialysis with cirrhosis population were comparable with the observed value (3602 ng/mL), which fell between the predicted concentrations in the absence and presence of mexiletine (3043 [718-8499] and 5914 [880-20,624] ng/mL, respectively).",Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32249350/),[ng] / [ml],5914,16637,DB00379,Mexiletine
,8095536,steady-state levels,"The low and high steady-state levels of mexiletine in blood plasma were attained at 0.259 +/- 0.123 and 1.616 +/- 0.475 micrograms mL-1, respectively, within the first 1-2 h after drug administration.",Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),[μg] / [ml],0.259,17326,DB00379,Mexiletine
,8095536,steady-state levels,"The low and high steady-state levels of mexiletine in blood plasma were attained at 0.259 +/- 0.123 and 1.616 +/- 0.475 micrograms mL-1, respectively, within the first 1-2 h after drug administration.",Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),[μg] / [ml],1.616,17327,DB00379,Mexiletine
,8095536,saliva to plasma drug concentration ratios (S/P ratio,"In parotid saliva, the high steady-state produced greater saliva to plasma drug concentration ratios (S/P ratio, 0.475 +/- 0.160) than that (0.386 +/- 0.131) at the low steady-state (P < 0.05).",Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),,0.475,17328,DB00379,Mexiletine
,8095536,saliva to plasma drug concentration ratios (S/P ratio,"In parotid saliva, the high steady-state produced greater saliva to plasma drug concentration ratios (S/P ratio, 0.475 +/- 0.160) than that (0.386 +/- 0.131) at the low steady-state (P < 0.05).",Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),,0.386,17329,DB00379,Mexiletine
,8095536,S/P ratio,The S/P ratio for mandibular saliva at the high (0.204 +/- 0.060) steady-state was also greater than that at the low (0.158 +/- 0.050) steady-state (P < 0.01).,Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),,0.204,17330,DB00379,Mexiletine
,8095536,S/P ratio,The S/P ratio for mandibular saliva at the high (0.204 +/- 0.060) steady-state was also greater than that at the low (0.158 +/- 0.050) steady-state (P < 0.01).,Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),,0.158,17331,DB00379,Mexiletine
,9725491,AUCss(0-8),"The following differences (p < 0.05) between R(-) and S(+) enantiomers, respectively, were found: MEX AUCss(0-8) 2.34 (1.84-2.85) vs 2.55 (1.97-3.13) microg.ml(-1) x h(-1); MEX CL/f 11.27 (7.77-14.77) vs 10.46 (7.18-13.74)ml.min(-1).",Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),[μg] / [h·ml],2.34,26746,DB00379,Mexiletine
,9725491,AUCss(0-8),"The following differences (p < 0.05) between R(-) and S(+) enantiomers, respectively, were found: MEX AUCss(0-8) 2.34 (1.84-2.85) vs 2.55 (1.97-3.13) microg.ml(-1) x h(-1); MEX CL/f 11.27 (7.77-14.77) vs 10.46 (7.18-13.74)ml.min(-1).",Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),[μg] / [h·ml],2.55,26747,DB00379,Mexiletine
,9725491,CL/f,"The following differences (p < 0.05) between R(-) and S(+) enantiomers, respectively, were found: MEX AUCss(0-8) 2.34 (1.84-2.85) vs 2.55 (1.97-3.13) microg.ml(-1) x h(-1); MEX CL/f 11.27 (7.77-14.77) vs 10.46 (7.18-13.74)ml.min(-1).",Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),[ml] / [min],11.27,26748,DB00379,Mexiletine
,9725491,CL/f,"The following differences (p < 0.05) between R(-) and S(+) enantiomers, respectively, were found: MEX AUCss(0-8) 2.34 (1.84-2.85) vs 2.55 (1.97-3.13) microg.ml(-1) x h(-1); MEX CL/f 11.27 (7.77-14.77) vs 10.46 (7.18-13.74)ml.min(-1).",Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),[ml] / [min],10.46,26749,DB00379,Mexiletine
,9725491,Cmax,Kg(-1); HMM Cmax 38.26 (24.3-52.22) vs 16.73 (10.1-23.29)ng.ml(-1); HMM Tmax 4.71 (2.67-6.76) vs 3.29 (1.24-5.33) h and HMM AUCss(0-8) 253.50 (165.39-341.61) vs 103.70 (69.51-137.90)ng.ml(-1).h(-1).,Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),[ng] / [ml],38.26,26750,DB00379,Mexiletine
,9725491,Cmax,Kg(-1); HMM Cmax 38.26 (24.3-52.22) vs 16.73 (10.1-23.29)ng.ml(-1); HMM Tmax 4.71 (2.67-6.76) vs 3.29 (1.24-5.33) h and HMM AUCss(0-8) 253.50 (165.39-341.61) vs 103.70 (69.51-137.90)ng.ml(-1).h(-1).,Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),[ng] / [ml],16.73,26751,DB00379,Mexiletine
,9725491,Tmax,Kg(-1); HMM Cmax 38.26 (24.3-52.22) vs 16.73 (10.1-23.29)ng.ml(-1); HMM Tmax 4.71 (2.67-6.76) vs 3.29 (1.24-5.33) h and HMM AUCss(0-8) 253.50 (165.39-341.61) vs 103.70 (69.51-137.90)ng.ml(-1).h(-1).,Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),h,4.71,26752,DB00379,Mexiletine
,9725491,Tmax,Kg(-1); HMM Cmax 38.26 (24.3-52.22) vs 16.73 (10.1-23.29)ng.ml(-1); HMM Tmax 4.71 (2.67-6.76) vs 3.29 (1.24-5.33) h and HMM AUCss(0-8) 253.50 (165.39-341.61) vs 103.70 (69.51-137.90)ng.ml(-1).h(-1).,Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),h,3.29,26753,DB00379,Mexiletine
,9725491,AUCss(0-8),Kg(-1); HMM Cmax 38.26 (24.3-52.22) vs 16.73 (10.1-23.29)ng.ml(-1); HMM Tmax 4.71 (2.67-6.76) vs 3.29 (1.24-5.33) h and HMM AUCss(0-8) 253.50 (165.39-341.61) vs 103.70 (69.51-137.90)ng.ml(-1).h(-1).,Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),[ng] / [h·ml],253.50,26754,DB00379,Mexiletine
,9725491,AUCss(0-8),Kg(-1); HMM Cmax 38.26 (24.3-52.22) vs 16.73 (10.1-23.29)ng.ml(-1); HMM Tmax 4.71 (2.67-6.76) vs 3.29 (1.24-5.33) h and HMM AUCss(0-8) 253.50 (165.39-341.61) vs 103.70 (69.51-137.90)ng.ml(-1).h(-1).,Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725491/),[ng] / [h·ml],103.70,26755,DB00379,Mexiletine
,2763576,R/S ratios,"Similarly, the R/S ratios in urine were 1.38 +/- 0.42 and 0.55 +/- 0.12 at 1 h and 72 h, respectively.",The pharmacokinetics of the enantiomers of mexiletine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763576/),,1.38,29060,DB00379,Mexiletine
,2763576,R/S ratios,"Similarly, the R/S ratios in urine were 1.38 +/- 0.42 and 0.55 +/- 0.12 at 1 h and 72 h, respectively.",The pharmacokinetics of the enantiomers of mexiletine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763576/),,0.55,29061,DB00379,Mexiletine
,2763576,terminal elimination half-life,"3. The terminal elimination half-life of S(+)mexiletine was 11.0 +/- 3.80 h, which was significantly greater (P less than 0.05) than that of the R(-) enantiomer, 9.10 +/- 2.90 h.",The pharmacokinetics of the enantiomers of mexiletine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763576/),h,11.0,29062,DB00379,Mexiletine
,2763576,terminal elimination half-life,"3. The terminal elimination half-life of S(+)mexiletine was 11.0 +/- 3.80 h, which was significantly greater (P less than 0.05) than that of the R(-) enantiomer, 9.10 +/- 2.90 h.",The pharmacokinetics of the enantiomers of mexiletine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763576/),h,9.10,29063,DB00379,Mexiletine
,6990666,half-life,The half-life may vary under certain circumstances and lies in the region of 10-16 hours.,"Baseline pharmacology, electrophysiology and pharmacokinetics of mexiletine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6990666/),h,10-16,30750,DB00379,Mexiletine
,1429987,flow-rate,"An aliquot of the resulting solution was injected onto a reversed-phase C18 column and resolution of mexiletine diastereoisomeric derivatives was achieved with a mobile phase consisting of methanol-50 mM sodium acetate (65:35), at a flow-rate of 1 ml/min.",Improved high-performance liquid chromatographic assay for the stereoselective determination of mexiletine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1429987/),[ml] / [min],1,34037,DB00379,Mexiletine
,1429987,retention times,"The retention times of S-(+)- and R-(-)-mexiletine diastereoisomeric peaks were 14 and 15 min, respectively.",Improved high-performance liquid chromatographic assay for the stereoselective determination of mexiletine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1429987/),min,14,34038,DB00379,Mexiletine
,1429987,retention times,"The retention times of S-(+)- and R-(-)-mexiletine diastereoisomeric peaks were 14 and 15 min, respectively.",Improved high-performance liquid chromatographic assay for the stereoselective determination of mexiletine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1429987/),min,15,34039,DB00379,Mexiletine
,3709636,total clearance,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),[ml] / [h·kg],2.31,44187,DB00379,Mexiletine
,3709636,total clearance,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),[ml] / [h·kg],8.27,44188,DB00379,Mexiletine
,3709636,total elimination rate constant,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),1/[h],0.059,44189,DB00379,Mexiletine
,3709636,total elimination rate constant,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),1/[h],0.353,44190,DB00379,Mexiletine
,3709636,elimination half-life,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),h,28.7,44191,DB00379,Mexiletine
,3709636,elimination half-life,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),h,9.9,44192,DB00379,Mexiletine
,3709636,half-life,The antipyrine half-life was 38.3 h in the patients and 14.7 h in the controls.,Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),h,38.3,44193,DB00379,Mexiletine
,3709636,half-life,The antipyrine half-life was 38.3 h in the patients and 14.7 h in the controls.,Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),h,14.7,44194,DB00379,Mexiletine
,1489940,fraction,The fraction of mexiletine metabolized to hydroxy-methyl-mexiletine was lower for multiple-dose administration (about 18 per cent) than for the single dose (about 42 per cent).,Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single- and multiple-dose administration of a sustained-release mexiletine formulation. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489940/),,18,48754,DB00379,Mexiletine
,1489940,fraction,The fraction of mexiletine metabolized to hydroxy-methyl-mexiletine was lower for multiple-dose administration (about 18 per cent) than for the single dose (about 42 per cent).,Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single- and multiple-dose administration of a sustained-release mexiletine formulation. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489940/),,42,48755,DB00379,Mexiletine
,11240973,area under the concentration-time curve,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[h·μg] / [ml],10.4,53241,DB00379,Mexiletine
,11240973,area under the concentration-time curve,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[h·μg] / [ml],6.70,53242,DB00379,Mexiletine
,11240973,serum peak concentration,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[h·μg] / [ml],6.70,53243,DB00379,Mexiletine
,11240973,serum peak concentration,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[μg] / [ml],0.623,53244,DB00379,Mexiletine
,11240973,serum peak concentration,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[μg] / [ml],0.536,53245,DB00379,Mexiletine
greater,1601956,recovery,Overall the recovery of each compound is reproducible and greater than 75%.,Simultaneous determination of mexiletine and four hydroxylated metabolites in human serum by high-performance liquid chromatography and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1601956/),%,75,60661,DB00379,Mexiletine
,1601956,lower limit of detection,The lower limit of detection is 2 ng/ml for mexiletine and its metabolites.,Simultaneous determination of mexiletine and four hydroxylated metabolites in human serum by high-performance liquid chromatography and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1601956/),[ng] / [ml],2,60662,DB00379,Mexiletine
,1788983,systemic clearance,2. The pharmacokinetic parameters calculated from the serum data showed a 32% greater systemic clearance (162 ml/min per kg vs 123 ml/min per kg) and a 22% greater steady-state volume of distribution (9.0 l/kg vs 7.4 l/kg) for R(-)-mexiletine relative to the S(+)-enantiomer.,Tissue distribution of mexiletine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788983/),[ml] / [kg·min],162,63175,DB00379,Mexiletine
,1788983,systemic clearance,2. The pharmacokinetic parameters calculated from the serum data showed a 32% greater systemic clearance (162 ml/min per kg vs 123 ml/min per kg) and a 22% greater steady-state volume of distribution (9.0 l/kg vs 7.4 l/kg) for R(-)-mexiletine relative to the S(+)-enantiomer.,Tissue distribution of mexiletine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788983/),[ml] / [kg·min],123,63176,DB00379,Mexiletine
,1788983,steady-state volume of distribution,2. The pharmacokinetic parameters calculated from the serum data showed a 32% greater systemic clearance (162 ml/min per kg vs 123 ml/min per kg) and a 22% greater steady-state volume of distribution (9.0 l/kg vs 7.4 l/kg) for R(-)-mexiletine relative to the S(+)-enantiomer.,Tissue distribution of mexiletine enantiomers in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788983/),[l] / [kg],9.0,63177,DB00379,Mexiletine
,1788983,steady-state volume of distribution,2. The pharmacokinetic parameters calculated from the serum data showed a 32% greater systemic clearance (162 ml/min per kg vs 123 ml/min per kg) and a 22% greater steady-state volume of distribution (9.0 l/kg vs 7.4 l/kg) for R(-)-mexiletine relative to the S(+)-enantiomer.,Tissue distribution of mexiletine enantiomers in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788983/),[l] / [kg],7.4,63178,DB00379,Mexiletine
,1788983,terminal elimination half-lives,"However, the terminal elimination half-lives of the enantiomers (1.4 and 1.3 h for R(-)- and S(+)-mexiletine, respectively) did not exhibit stereoselectivity.",Tissue distribution of mexiletine enantiomers in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788983/),h,1.4,63179,DB00379,Mexiletine
,1788983,terminal elimination half-lives,"However, the terminal elimination half-lives of the enantiomers (1.4 and 1.3 h for R(-)- and S(+)-mexiletine, respectively) did not exhibit stereoselectivity.",Tissue distribution of mexiletine enantiomers in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788983/),h,1.3,63180,DB00379,Mexiletine
greater,1788983,tissue/serum ratios,"High tissue/serum ratios (greater than 20 for both enantiomers) were observed in lungs, brain and kidneys.",Tissue distribution of mexiletine enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788983/),,20,63181,DB00379,Mexiletine
,7226704,t 1/2 gamma,With this procedure one common value for the plasma t 1/2 of elimination was obtained (t 1/2 gamma = 6.34 +/- 1.5 hr).,Kinetics and bioavailability of mexiletine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226704/),h,6.34,63760,DB00379,Mexiletine
,7226704,total volume of distribution (Vdtot),Mean values for the total volume of distribution (Vdtot) and the total body clearance (Cltot) were 5.5 l/kg and 10.3 ml/min/kg.,Kinetics and bioavailability of mexiletine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226704/),[l] / [kg],5.5,63761,DB00379,Mexiletine
,7226704,total body clearance (Cltot),Mean values for the total volume of distribution (Vdtot) and the total body clearance (Cltot) were 5.5 l/kg and 10.3 ml/min/kg.,Kinetics and bioavailability of mexiletine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226704/),[ml] / [kg·min],10.3,63762,DB00379,Mexiletine
,7226704,peak plasma concentrations (Cmax,"After capsules, peak plasma concentrations (Cmax = 0.77 microgram/ml) were reached after 2.2 hr.",Kinetics and bioavailability of mexiletine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226704/),[μg] / [ml],0.77,63763,DB00379,Mexiletine
,7226704,maximum of concentration (Cmax,and the sustained-release form built up a flat maximum of concentration (Cmax = 0.34 microgram/ml) after 9.2 hr.,Kinetics and bioavailability of mexiletine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226704/),[μg] / [ml],0.34,63764,DB00379,Mexiletine
,7226704,bioavaila,"Mexiletine is highly bioavailable, almost identical for the two oral formulations: 87.3% (capsule) and 78.7% (slow release).",Kinetics and bioavailability of mexiletine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226704/),%,87.3,63765,DB00379,Mexiletine
,7226704,bioavaila,"Mexiletine is highly bioavailable, almost identical for the two oral formulations: 87.3% (capsule) and 78.7% (slow release).",Kinetics and bioavailability of mexiletine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226704/),%,78.7,63766,DB00379,Mexiletine
,17077526,clearance,"Mexiletine clearance was significantly lower in the CHF group when compared with the Non-CHF group (0.264+/-0.093 vs. 0.393+/-0.082 l/h/kg, mean+/-S.D., p<0.05).",Effect of congestive heart failure on mexiletine pharmacokinetics in a Japanese population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17077526/),[l] / [h·kg],0.264,63803,DB00379,Mexiletine
,17077526,clearance,"Mexiletine clearance was significantly lower in the CHF group when compared with the Non-CHF group (0.264+/-0.093 vs. 0.393+/-0.082 l/h/kg, mean+/-S.D., p<0.05).",Effect of congestive heart failure on mexiletine pharmacokinetics in a Japanese population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17077526/),[l] / [h·kg],0.393,63804,DB00379,Mexiletine
,4006366,absorption t1/2,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,0.20,69837,DB00379,Mexiletine
,4006366,absorption t1/2,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,0.61,69838,DB00379,Mexiletine
,4006366,time to peak mexi,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,1.13,69839,DB00379,Mexiletine
,4006366,time to peak mexi,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,1.88,69840,DB00379,Mexiletine
,4006366,plasma concentration,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),mg,0.74,69841,DB00379,Mexiletine
,4006366,plasma concentration,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),mg,0.59,69842,DB00379,Mexiletine
,10217339,partial metabolic clearance,"Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 +/- 48 mL/min to 106 +/- 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively.",Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217339/),[ml] / [min],126,71722,DB00379,Mexiletine
,10217339,partial metabolic clearance,"Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 +/- 48 mL/min to 106 +/- 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively.",Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217339/),[ml] / [min],106,71723,DB00379,Mexiletine
,10217339,partial metabolic clearance,"Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 +/- 48 mL/min to 106 +/- 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively.",Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217339/),[ml] / [min],152.6,71724,DB00379,Mexiletine
,10217339,partial metabolic clearance,"Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 +/- 48 mL/min to 106 +/- 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively.",Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217339/),[ml] / [min],109,71725,DB00379,Mexiletine
,3584372,Maximum recovery,Maximum recovery of the enantiomers from plasma was 83% and was observed when plasma proteins were precipitated with a mixture of barium hydroxide-zinc sulphate.,Stereoselective analysis of the enantiomers of mexiletine by high-performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584372/),%,83,80428,DB00379,Mexiletine
,3584372,minimum detectable quantity,"The minimum detectable quantity of each enantiomer in plasma was 5 ng/ml at a signal-to-noise ratio of 5:1, representing 100 pg injected.",Stereoselective analysis of the enantiomers of mexiletine by high-performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584372/),[ng] / [ml],5,80429,DB00379,Mexiletine
,3584372,signal-to-noise ratio,"The minimum detectable quantity of each enantiomer in plasma was 5 ng/ml at a signal-to-noise ratio of 5:1, representing 100 pg injected.",Stereoselective analysis of the enantiomers of mexiletine by high-performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584372/),,5:1,80430,DB00379,Mexiletine
,3584372,apparent elimination half-lives,"The apparent elimination half-lives determined from the plasma data were 12.1 and 14.1 h for the R(-) and S(+) enantiomers, respectively.",Stereoselective analysis of the enantiomers of mexiletine by high-performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584372/),h,12.1,80431,DB00379,Mexiletine
,3584372,apparent elimination half-lives,"The apparent elimination half-lives determined from the plasma data were 12.1 and 14.1 h for the R(-) and S(+) enantiomers, respectively.",Stereoselective analysis of the enantiomers of mexiletine by high-performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584372/),h,14.1,80432,DB00379,Mexiletine
,3584372,cumulative urinary excretion amounts,"The cumulative urinary excretion amounts of R(-)- and S(+)-mexiletine were found to be 8.01 and 10.46 mg, respectively.",Stereoselective analysis of the enantiomers of mexiletine by high-performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584372/),mg,8.01,80433,DB00379,Mexiletine
,3584372,cumulative urinary excretion amounts,"The cumulative urinary excretion amounts of R(-)- and S(+)-mexiletine were found to be 8.01 and 10.46 mg, respectively.",Stereoselective analysis of the enantiomers of mexiletine by high-performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584372/),mg,10.46,80434,DB00379,Mexiletine
greater,6966453,apparent volume of distribution (Vd),The apparent volume of distribution (Vd) is greater than 500 1.,Pharmacokinetics of mexiletine in renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966453/),1,500,84404,DB00379,Mexiletine
,6966453,plasma half-time,The plasma half-time is 10 to 12 hours in healthy volunteers with a 70% plasma protein fixation.,Pharmacokinetics of mexiletine in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966453/),h,10 to 12,84405,DB00379,Mexiletine
,6966453,plasma half-time,The mean plasma half-time for these patients is 11.1 +/- 1.7 hours after a single i.v. injection of 1.5 mg/kg.,Pharmacokinetics of mexiletine in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966453/),h,11.1,84406,DB00379,Mexiletine
,6966453,plasma half-time,Our control group containing convalescents from acute myocardial infarct has a plasma half-time of only 5.9 hours.,Pharmacokinetics of mexiletine in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966453/),h,5.9,84407,DB00379,Mexiletine
,7355759,elimination half-life,Pharmacokinetic analysis indicated a mean elimination half-life of 12.6 +/- 1.6 hours following oral administration of mexiletine.,Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7355759/),h,12.6,85876,DB00379,Mexiletine
,18037598,retention times,"And the retention times for tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen were minimized to 11, 10 and 3.9 min, respectively.",Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18037598/),min,11,88918,DB00379,Mexiletine
,18037598,retention times,"And the retention times for tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen were minimized to 11, 10 and 3.9 min, respectively.",Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18037598/),min,10,88919,DB00379,Mexiletine
,18037598,retention times,"And the retention times for tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen were minimized to 11, 10 and 3.9 min, respectively.",Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18037598/),min,3.9,88920,DB00379,Mexiletine
,7104173,area under the plasma mexiletine concentration-time curve,3 The mean +/- s.d. area under the plasma mexiletine concentration-time curve decreased from 17.67 +/- 6.21 to 8.01 +/- 3.64 micrograms ml-1 h (P less than 0.003).,Enhanced metabolism of mexiletine after phenytoin administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104173/),[h·μg] / [ml],17.67,96627,DB00379,Mexiletine
,7104173,area under the plasma mexiletine concentration-time curve,3 The mean +/- s.d. area under the plasma mexiletine concentration-time curve decreased from 17.67 +/- 6.21 to 8.01 +/- 3.64 micrograms ml-1 h (P less than 0.003).,Enhanced metabolism of mexiletine after phenytoin administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104173/),[h·μg] / [ml],8.01,96628,DB00379,Mexiletine
,7104173,half-life of elimination,4 The mean +/- s.d. half-life of elimination of mexiletine decreased from 17.2 +/- 5.26 to 8.4 +/- 4.17 h (P less than 0.02) 5,Enhanced metabolism of mexiletine after phenytoin administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104173/),h,17.2,96629,DB00379,Mexiletine
,7104173,half-life of elimination,4 The mean +/- s.d. half-life of elimination of mexiletine decreased from 17.2 +/- 5.26 to 8.4 +/- 4.17 h (P less than 0.02) 5,Enhanced metabolism of mexiletine after phenytoin administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104173/),h,8.4,96630,DB00379,Mexiletine
,7151850,oral total body clearance (Cl),"The population averages of the pharmacokinetic parameters and their interindividual variability were: oral total body clearance (Cl) 0.38 l/h/kg +/- 43% (C.V.), apparent volume of distribution (Vd) 5.3 l/kg +/- 40%, absorption rate constant 3.1 h-1 +/- 205%, absorption time-lag 0.3 h.",Population pharmacokinetic parameters in patients treated with oral mexiletine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151850/),[l] / [h·kg],0.38,110641,DB00379,Mexiletine
,7151850,C.V.,"The population averages of the pharmacokinetic parameters and their interindividual variability were: oral total body clearance (Cl) 0.38 l/h/kg +/- 43% (C.V.), apparent volume of distribution (Vd) 5.3 l/kg +/- 40%, absorption rate constant 3.1 h-1 +/- 205%, absorption time-lag 0.3 h.",Population pharmacokinetic parameters in patients treated with oral mexiletine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151850/),[l] / [h·kg],0.38,110642,DB00379,Mexiletine
,7151850,apparent volume of distribution (Vd),"The population averages of the pharmacokinetic parameters and their interindividual variability were: oral total body clearance (Cl) 0.38 l/h/kg +/- 43% (C.V.), apparent volume of distribution (Vd) 5.3 l/kg +/- 40%, absorption rate constant 3.1 h-1 +/- 205%, absorption time-lag 0.3 h.",Population pharmacokinetic parameters in patients treated with oral mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151850/),[l] / [kg],5.3,110643,DB00379,Mexiletine
,7151850,absorption rate constant,"The population averages of the pharmacokinetic parameters and their interindividual variability were: oral total body clearance (Cl) 0.38 l/h/kg +/- 43% (C.V.), apparent volume of distribution (Vd) 5.3 l/kg +/- 40%, absorption rate constant 3.1 h-1 +/- 205%, absorption time-lag 0.3 h.",Population pharmacokinetic parameters in patients treated with oral mexiletine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151850/),1/[h],3.1,110644,DB00379,Mexiletine
,7151850,absorption time-lag,"The population averages of the pharmacokinetic parameters and their interindividual variability were: oral total body clearance (Cl) 0.38 l/h/kg +/- 43% (C.V.), apparent volume of distribution (Vd) 5.3 l/kg +/- 40%, absorption rate constant 3.1 h-1 +/- 205%, absorption time-lag 0.3 h.",Population pharmacokinetic parameters in patients treated with oral mexiletine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151850/),h,0.3,110645,DB00379,Mexiletine
,9914650,maximum plasma concentration Cmax,"The pharmacokinetic parameters calculated for (-)-(R)-N-hydroxymexiletine glucuronide are presented as means (95% confidence interval): maximum plasma concentration Cmax = 194.0 ng.ml-1 (154.3-233.7), time to maximum plasma concentration tmax = 1.4 hr (0.3-2.5), area under the plasma concentration versus time curve AUC0-24 = 2099.2 ng.h.ml-1 (1585.6-2612.6), elimination half-life t1/2 beta = 12.8 hr (9.9-15.6) and extent of conjugation of 31.6% (24.3-38.9%).",Enantioselectivity in the metabolism of mexiletine by conjugation in female patients with the arrhythmic form of chronic Chagas' heart disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914650/),[ng] / [ml],194.0,111137,DB00379,Mexiletine
,9914650,time to maximum plasma concentration tmax,"The pharmacokinetic parameters calculated for (-)-(R)-N-hydroxymexiletine glucuronide are presented as means (95% confidence interval): maximum plasma concentration Cmax = 194.0 ng.ml-1 (154.3-233.7), time to maximum plasma concentration tmax = 1.4 hr (0.3-2.5), area under the plasma concentration versus time curve AUC0-24 = 2099.2 ng.h.ml-1 (1585.6-2612.6), elimination half-life t1/2 beta = 12.8 hr (9.9-15.6) and extent of conjugation of 31.6% (24.3-38.9%).",Enantioselectivity in the metabolism of mexiletine by conjugation in female patients with the arrhythmic form of chronic Chagas' heart disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914650/),h,1.4,111138,DB00379,Mexiletine
,9914650,area under the plasma concentration versus time curve AUC0-24,"The pharmacokinetic parameters calculated for (-)-(R)-N-hydroxymexiletine glucuronide are presented as means (95% confidence interval): maximum plasma concentration Cmax = 194.0 ng.ml-1 (154.3-233.7), time to maximum plasma concentration tmax = 1.4 hr (0.3-2.5), area under the plasma concentration versus time curve AUC0-24 = 2099.2 ng.h.ml-1 (1585.6-2612.6), elimination half-life t1/2 beta = 12.8 hr (9.9-15.6) and extent of conjugation of 31.6% (24.3-38.9%).",Enantioselectivity in the metabolism of mexiletine by conjugation in female patients with the arrhythmic form of chronic Chagas' heart disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914650/),[h·ng] / [ml],2099.2,111139,DB00379,Mexiletine
,9914650,elimination half-life t1/2 beta,"The pharmacokinetic parameters calculated for (-)-(R)-N-hydroxymexiletine glucuronide are presented as means (95% confidence interval): maximum plasma concentration Cmax = 194.0 ng.ml-1 (154.3-233.7), time to maximum plasma concentration tmax = 1.4 hr (0.3-2.5), area under the plasma concentration versus time curve AUC0-24 = 2099.2 ng.h.ml-1 (1585.6-2612.6), elimination half-life t1/2 beta = 12.8 hr (9.9-15.6) and extent of conjugation of 31.6% (24.3-38.9%).",Enantioselectivity in the metabolism of mexiletine by conjugation in female patients with the arrhythmic form of chronic Chagas' heart disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914650/),h,12.8,111140,DB00379,Mexiletine
,9914650,extent of conjugation,"The pharmacokinetic parameters calculated for (-)-(R)-N-hydroxymexiletine glucuronide are presented as means (95% confidence interval): maximum plasma concentration Cmax = 194.0 ng.ml-1 (154.3-233.7), time to maximum plasma concentration tmax = 1.4 hr (0.3-2.5), area under the plasma concentration versus time curve AUC0-24 = 2099.2 ng.h.ml-1 (1585.6-2612.6), elimination half-life t1/2 beta = 12.8 hr (9.9-15.6) and extent of conjugation of 31.6% (24.3-38.9%).",Enantioselectivity in the metabolism of mexiletine by conjugation in female patients with the arrhythmic form of chronic Chagas' heart disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914650/),%,31.6,111141,DB00379,Mexiletine
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00379,Mexiletine
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00379,Mexiletine
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00379,Mexiletine
,8578769,peak serum total mexiletine concentration,2. The mean peak serum total mexiletine concentration of 217 +/- 69 ng/ml for R(-)-mexiletine was found to be significantly greater than a mean of 197 +/- 56 ng/ml for S(+)-mexiletine.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),[ng] / [ml],217,115478,DB00379,Mexiletine
,8578769,peak serum total mexiletine concentration,2. The mean peak serum total mexiletine concentration of 217 +/- 69 ng/ml for R(-)-mexiletine was found to be significantly greater than a mean of 197 +/- 56 ng/ml for S(+)-mexiletine.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),[ng] / [ml],197,115479,DB00379,Mexiletine
,8578769,serum protein binding,A serum pH ranging from 6.3 to 9.4 was found to correlate with serum protein binding of the enantiomers from approximately 30-80% respectively.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),%,30,115480,DB00379,Mexiletine
,8578769,R(-)/S(+) ratios,"Within the same serum pH range, the serum free drug R(-)/S(+) ratios were found to decrease from 1.0 to 0.7 respectively.","Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,1.0,115481,DB00379,Mexiletine
,8578769,R(-)/S(+) ratios,"Within the same serum pH range, the serum free drug R(-)/S(+) ratios were found to decrease from 1.0 to 0.7 respectively.","Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,0.7,115482,DB00379,Mexiletine
,8578769,serum free fraction,"At serum pH7.4, a mean serum free fraction of 0.57 +/- 0.7 and 0.56 +/- 0.6 were observed for R(-) and S(+)-mexiletine respectively.","Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,0.57,115483,DB00379,Mexiletine
,8578769,serum free fraction,"At serum pH7.4, a mean serum free fraction of 0.57 +/- 0.7 and 0.56 +/- 0.6 were observed for R(-) and S(+)-mexiletine respectively.","Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,0.56,115484,DB00379,Mexiletine
,8578769,area under the concentration-time curve ratios,4. The overall mean saliva/serum-free mexiletine enantiomer area under the concentration-time curve ratios of 6.10 +/- 2.82 and 7.49 +/- 3.48 for R(-)- and S(+)-mexiletine respectively were found to be significantly different.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,6.10,115485,DB00379,Mexiletine
,8578769,area under the concentration-time curve ratios,4. The overall mean saliva/serum-free mexiletine enantiomer area under the concentration-time curve ratios of 6.10 +/- 2.82 and 7.49 +/- 3.48 for R(-)- and S(+)-mexiletine respectively were found to be significantly different.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,7.49,115486,DB00379,Mexiletine
,8578769,red blood cells to serum-free drug concentration ratios,5. The mean mexiletine red blood cells to serum-free drug concentration ratios among 11 subjects studied were found to range from 0.6 to 1.4 for R(-)-mexiletine and from 0.6 to 1.8 for S(+)-mexiletine.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,0.6 to 1.4,115487,DB00379,Mexiletine
,8578769,red blood cells to serum-free drug concentration ratios,5. The mean mexiletine red blood cells to serum-free drug concentration ratios among 11 subjects studied were found to range from 0.6 to 1.4 for R(-)-mexiletine and from 0.6 to 1.8 for S(+)-mexiletine.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,0.6 to 1.8,115488,DB00379,Mexiletine
,8578769,concentration ratio,This data together with an overall red blood cell mean R(-)/S(+)-mexiletine concentration ratio of 0.91 +/- 0.13 suggested a non-stereoselective and passive diffusion of the enantiomers into red blood cells.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),,0.91,115489,DB00379,Mexiletine
,8578769,percent urinary recovery,6. The cumulative amounts of unchanged R(-)- and S(+)-mexiletine in the urine were found to be variable among the 12 subjects with a mean percent urinary recovery of 3.49 +/- 3.35% for R(-)-mexiletine and 3.68 +/- 3.94% for S(+)-mexiletine.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),%,3.49,115490,DB00379,Mexiletine
,8578769,percent urinary recovery,6. The cumulative amounts of unchanged R(-)- and S(+)-mexiletine in the urine were found to be variable among the 12 subjects with a mean percent urinary recovery of 3.49 +/- 3.35% for R(-)-mexiletine and 3.68 +/- 3.94% for S(+)-mexiletine.,"Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578769/),%,3.68,115491,DB00379,Mexiletine
,12937870,AUC,"Mean area under the concentration-time curve (AUC) and t(1/2) of MX were significantly ( P<0.05) higher in the CYP2D6*10/*5 group (AUC 11.23+/-3.05 micro g.h/ml; t(1/2) 15.5+/-3.2 h) than in the CYP2D6*1/*1 (AUC 5.53+/-1.01 micro g.h/ml; t(1/2) 8.1+/-1.6 h) and CYP2D6*10/*10 (AUC 7.32+/-2.36 micro g.h/ml; t(1/2) 10.8+/-2.8 h) groups, but there was no significant difference between the CYP2D6*1/*1 and CYP2D6*10/*10 groups.",Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12937870/),[h·μg] / [ml],11.23,116871,DB00379,Mexiletine
,12937870,t(1/2),"Mean area under the concentration-time curve (AUC) and t(1/2) of MX were significantly ( P<0.05) higher in the CYP2D6*10/*5 group (AUC 11.23+/-3.05 micro g.h/ml; t(1/2) 15.5+/-3.2 h) than in the CYP2D6*1/*1 (AUC 5.53+/-1.01 micro g.h/ml; t(1/2) 8.1+/-1.6 h) and CYP2D6*10/*10 (AUC 7.32+/-2.36 micro g.h/ml; t(1/2) 10.8+/-2.8 h) groups, but there was no significant difference between the CYP2D6*1/*1 and CYP2D6*10/*10 groups.",Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12937870/),h,15.5,116872,DB00379,Mexiletine
,12937870,AUC,"Mean area under the concentration-time curve (AUC) and t(1/2) of MX were significantly ( P<0.05) higher in the CYP2D6*10/*5 group (AUC 11.23+/-3.05 micro g.h/ml; t(1/2) 15.5+/-3.2 h) than in the CYP2D6*1/*1 (AUC 5.53+/-1.01 micro g.h/ml; t(1/2) 8.1+/-1.6 h) and CYP2D6*10/*10 (AUC 7.32+/-2.36 micro g.h/ml; t(1/2) 10.8+/-2.8 h) groups, but there was no significant difference between the CYP2D6*1/*1 and CYP2D6*10/*10 groups.",Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12937870/),[h·μg] / [ml],5.53,116873,DB00379,Mexiletine
,12937870,t(1/2),"Mean area under the concentration-time curve (AUC) and t(1/2) of MX were significantly ( P<0.05) higher in the CYP2D6*10/*5 group (AUC 11.23+/-3.05 micro g.h/ml; t(1/2) 15.5+/-3.2 h) than in the CYP2D6*1/*1 (AUC 5.53+/-1.01 micro g.h/ml; t(1/2) 8.1+/-1.6 h) and CYP2D6*10/*10 (AUC 7.32+/-2.36 micro g.h/ml; t(1/2) 10.8+/-2.8 h) groups, but there was no significant difference between the CYP2D6*1/*1 and CYP2D6*10/*10 groups.",Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12937870/),h,8.1,116874,DB00379,Mexiletine
,12937870,AUC,"Mean area under the concentration-time curve (AUC) and t(1/2) of MX were significantly ( P<0.05) higher in the CYP2D6*10/*5 group (AUC 11.23+/-3.05 micro g.h/ml; t(1/2) 15.5+/-3.2 h) than in the CYP2D6*1/*1 (AUC 5.53+/-1.01 micro g.h/ml; t(1/2) 8.1+/-1.6 h) and CYP2D6*10/*10 (AUC 7.32+/-2.36 micro g.h/ml; t(1/2) 10.8+/-2.8 h) groups, but there was no significant difference between the CYP2D6*1/*1 and CYP2D6*10/*10 groups.",Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12937870/),[h·μg] / [ml],7.32,116875,DB00379,Mexiletine
,12937870,t(1/2),"Mean area under the concentration-time curve (AUC) and t(1/2) of MX were significantly ( P<0.05) higher in the CYP2D6*10/*5 group (AUC 11.23+/-3.05 micro g.h/ml; t(1/2) 15.5+/-3.2 h) than in the CYP2D6*1/*1 (AUC 5.53+/-1.01 micro g.h/ml; t(1/2) 8.1+/-1.6 h) and CYP2D6*10/*10 (AUC 7.32+/-2.36 micro g.h/ml; t(1/2) 10.8+/-2.8 h) groups, but there was no significant difference between the CYP2D6*1/*1 and CYP2D6*10/*10 groups.",Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12937870/),h,10.8,116876,DB00379,Mexiletine
,8739823,area under the concentration curves (AUC),"The area under the concentration curves (AUC) after administration of mexiletine alone and in combination with fluconazole 200 mg/day were 6.63 and 7.31 micrograms.h.ml-1, respectively.",Lack of a kinetic interaction between fluconazole and mexiletine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739823/),[h·μg] / [ml],6.63,126317,DB00379,Mexiletine
,8739823,area under the concentration curves (AUC),"The area under the concentration curves (AUC) after administration of mexiletine alone and in combination with fluconazole 200 mg/day were 6.63 and 7.31 micrograms.h.ml-1, respectively.",Lack of a kinetic interaction between fluconazole and mexiletine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739823/),[h·μg] / [ml],7.31,126318,DB00379,Mexiletine
,19789372,peak plasma concentration,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[ng] / [ml],1.8,132457,DB00379,Mexiletine
,19789372,peak plasma concentration,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[ng] / [ml],5.3,132458,DB00379,Mexiletine
,19789372,area under the curve,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[h·ng] / [ml],4.5,132459,DB00379,Mexiletine
,19789372,area under the curve,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[h·ng] / [ml],15.4,132460,DB00379,Mexiletine
,19789372,half-life,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),h,1.3,132461,DB00379,Mexiletine
,19789372,half-life,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),h,1.8,132462,DB00379,Mexiletine
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],33.5,135472,DB00379,Mexiletine
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],17.9,135473,DB00379,Mexiletine
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],32.3,135474,DB00379,Mexiletine
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],19.3,135475,DB00379,Mexiletine
,9743254,CL/F,"The final pharmacokinetic parameters are, CL/F=0.580-0.00369 x AGE (l/h/kg) and Vd/F=6.63 (l/kg).",Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743254/),[l] / [h·kg],0.580-0.00369,138253,DB00379,Mexiletine
,9743254,Vd/F,"The final pharmacokinetic parameters are, CL/F=0.580-0.00369 x AGE (l/h/kg) and Vd/F=6.63 (l/kg).",Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743254/),[l] / [kg],6.63,138254,DB00379,Mexiletine
,1914365,(trough) levels,Mean predose (trough) levels rose from 8.1 +/- 0.1 microgram.,Mexiletine effects on theophylline disposition. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),μg,8.1,140290,DB00379,Mexiletine
,1914365,AUC(0-12),ml-1 and AUC(0-12) from 96.8 +/- 9.1 to 160.2 +/- 3.7 micrograms.,Mexiletine effects on theophylline disposition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),μg,96.8,140291,DB00379,Mexiletine
,1914365,AUC(0-12),ml-1 and AUC(0-12) from 96.8 +/- 9.1 to 160.2 +/- 3.7 micrograms.,Mexiletine effects on theophylline disposition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),μg,160.2,140292,DB00379,Mexiletine
,1914365,Plasma clearance,Plasma clearance was reduced by mexiletine from 44.7 +/- 5.1 to 25.4 +/- 1.2 ml.,Mexiletine effects on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),ml,44.7,140293,DB00379,Mexiletine
,1914365,Plasma clearance,Plasma clearance was reduced by mexiletine from 44.7 +/- 5.1 to 25.4 +/- 1.2 ml.,Mexiletine effects on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914365/),ml,25.4,140294,DB00379,Mexiletine
,7894667,signal-to-noise ratio,The assay had a lower limit of quantitation at 2.5 ng/ml with a limit of detection measured at 0.5 ng/ml for each enantiomer in serum with a signal-to-noise ratio of 5:1.,"High-performance liquid chromatographic analysis using a highly sensitive fluorogenic reagent, 2-anthroyl chloride, and stereoselective determination of the enantiomers of mexiletine in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894667/),,5:1,141556,DB00379,Mexiletine
,7894667,terminal elimination half-lives,"The terminal elimination half-lives determined for total R(-)- and S(+)-mexiletine were 10.9 and 11.5 h, respectively.","High-performance liquid chromatographic analysis using a highly sensitive fluorogenic reagent, 2-anthroyl chloride, and stereoselective determination of the enantiomers of mexiletine in human serum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894667/),h,10.9,141557,DB00379,Mexiletine
,7894667,terminal elimination half-lives,"The terminal elimination half-lives determined for total R(-)- and S(+)-mexiletine were 10.9 and 11.5 h, respectively.","High-performance liquid chromatographic analysis using a highly sensitive fluorogenic reagent, 2-anthroyl chloride, and stereoselective determination of the enantiomers of mexiletine in human serum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894667/),h,11.5,141558,DB00379,Mexiletine
,7894667,serum free fractions,"The serum free fractions for R(-)- and S(+)-mexiletine were found to be 0.56 and 0.53, respectively.","High-performance liquid chromatographic analysis using a highly sensitive fluorogenic reagent, 2-anthroyl chloride, and stereoselective determination of the enantiomers of mexiletine in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894667/),,0.56,141559,DB00379,Mexiletine
,7894667,serum free fractions,"The serum free fractions for R(-)- and S(+)-mexiletine were found to be 0.56 and 0.53, respectively.","High-performance liquid chromatographic analysis using a highly sensitive fluorogenic reagent, 2-anthroyl chloride, and stereoselective determination of the enantiomers of mexiletine in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894667/),,0.53,141560,DB00379,Mexiletine
,6129140,elimination half-life,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,8.5,148024,DB00379,Mexiletine
,6129140,elimination half-life,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,5.0,148025,DB00379,Mexiletine
,6129140,nonrenal clearance,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],435,148026,DB00379,Mexiletine
,6129140,nonrenal clearance,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],711,148027,DB00379,Mexiletine
,6129140,amount,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,32,148028,DB00379,Mexiletine
,6129140,amount,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,18,148029,DB00379,Mexiletine
,6129140,excreted,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,32,148030,DB00379,Mexiletine
,6129140,excreted,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,18,148031,DB00379,Mexiletine
,6129140,half-life,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,11.8,148032,DB00379,Mexiletine
,6129140,half-life,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,5.5,148033,DB00379,Mexiletine
,6129140,clearance,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),ml,40,148034,DB00379,Mexiletine
,6129140,clearance,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],74,148035,DB00379,Mexiletine
,4030983,sensitivity,The sensitivity of the method is 0.007 micromol/l for all metabolites.,Selective and sensitive high-performance liquid chromatographic assay for the metabolites of nomifensine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030983/),[μM] / [l],0.007,158533,DB00379,Mexiletine
,4030983,Extraction efficiencies,"Extraction efficiencies are 84.6%, 75.8%, and 78.2% for 4'-hydroxynomifensine, 4'-hydroxy-3'-methoxynomifensine and 3'-hydroxy-4'-methoxynomifensine, respectively.",Selective and sensitive high-performance liquid chromatographic assay for the metabolites of nomifensine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030983/),%,84.6,158534,DB00379,Mexiletine
,4030983,Extraction efficiencies,"Extraction efficiencies are 84.6%, 75.8%, and 78.2% for 4'-hydroxynomifensine, 4'-hydroxy-3'-methoxynomifensine and 3'-hydroxy-4'-methoxynomifensine, respectively.",Selective and sensitive high-performance liquid chromatographic assay for the metabolites of nomifensine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030983/),%,75.8,158535,DB00379,Mexiletine
,4030983,Extraction efficiencies,"Extraction efficiencies are 84.6%, 75.8%, and 78.2% for 4'-hydroxynomifensine, 4'-hydroxy-3'-methoxynomifensine and 3'-hydroxy-4'-methoxynomifensine, respectively.",Selective and sensitive high-performance liquid chromatographic assay for the metabolites of nomifensine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030983/),%,78.2,158536,DB00379,Mexiletine
,32750364,maximum concentration (Cmax),"Pharmacokinetic experiments of JME-173 (10 mg/kg, orally) showed values of maximum concentration (Cmax), maximum time (Tmax), area under the blood concentration-time curve (AUC0-t) and area under the blood concentration-time curve from 0-Inf (AUC0-inf) of 163.3 ± 38.3 ng/mL, 1.2 ± 0.3 h, 729.4 ± 118.3 ng*h/ml and 868.9 ± 117.1 ng*h/ml (means ± S.E.M.), respectively.","Pharmacological profiling of JME-173, a novel mexiletine derivative combining dual anti-inflammatory/anti-spasmodic functions and limited action in Na+ channels. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32750364/),[ng] / [ml],163.3,161837,DB00379,Mexiletine
,32750364,maximum time (Tmax),"Pharmacokinetic experiments of JME-173 (10 mg/kg, orally) showed values of maximum concentration (Cmax), maximum time (Tmax), area under the blood concentration-time curve (AUC0-t) and area under the blood concentration-time curve from 0-Inf (AUC0-inf) of 163.3 ± 38.3 ng/mL, 1.2 ± 0.3 h, 729.4 ± 118.3 ng*h/ml and 868.9 ± 117.1 ng*h/ml (means ± S.E.M.), respectively.","Pharmacological profiling of JME-173, a novel mexiletine derivative combining dual anti-inflammatory/anti-spasmodic functions and limited action in Na+ channels. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32750364/),h,1.2,161838,DB00379,Mexiletine
,32750364,maximum time (Tmax),"Pharmacokinetic experiments of JME-173 (10 mg/kg, orally) showed values of maximum concentration (Cmax), maximum time (Tmax), area under the blood concentration-time curve (AUC0-t) and area under the blood concentration-time curve from 0-Inf (AUC0-inf) of 163.3 ± 38.3 ng/mL, 1.2 ± 0.3 h, 729.4 ± 118.3 ng*h/ml and 868.9 ± 117.1 ng*h/ml (means ± S.E.M.), respectively.","Pharmacological profiling of JME-173, a novel mexiletine derivative combining dual anti-inflammatory/anti-spasmodic functions and limited action in Na+ channels. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32750364/),[h·ng] / [ml],729.4,161839,DB00379,Mexiletine
,32750364,area under the blood concentration-time curve (AUC0-t),"Pharmacokinetic experiments of JME-173 (10 mg/kg, orally) showed values of maximum concentration (Cmax), maximum time (Tmax), area under the blood concentration-time curve (AUC0-t) and area under the blood concentration-time curve from 0-Inf (AUC0-inf) of 163.3 ± 38.3 ng/mL, 1.2 ± 0.3 h, 729.4 ± 118.3 ng*h/ml and 868.9 ± 117.1 ng*h/ml (means ± S.E.M.), respectively.","Pharmacological profiling of JME-173, a novel mexiletine derivative combining dual anti-inflammatory/anti-spasmodic functions and limited action in Na+ channels. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32750364/),h,1.2,161840,DB00379,Mexiletine
,32750364,area under the blood concentration-time curve (AUC0-t),"Pharmacokinetic experiments of JME-173 (10 mg/kg, orally) showed values of maximum concentration (Cmax), maximum time (Tmax), area under the blood concentration-time curve (AUC0-t) and area under the blood concentration-time curve from 0-Inf (AUC0-inf) of 163.3 ± 38.3 ng/mL, 1.2 ± 0.3 h, 729.4 ± 118.3 ng*h/ml and 868.9 ± 117.1 ng*h/ml (means ± S.E.M.), respectively.","Pharmacological profiling of JME-173, a novel mexiletine derivative combining dual anti-inflammatory/anti-spasmodic functions and limited action in Na+ channels. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32750364/),[h·ng] / [ml],729.4,161841,DB00379,Mexiletine
,32750364,area under the blood concentration-time curve from 0-Inf (AUC0-inf),"Pharmacokinetic experiments of JME-173 (10 mg/kg, orally) showed values of maximum concentration (Cmax), maximum time (Tmax), area under the blood concentration-time curve (AUC0-t) and area under the blood concentration-time curve from 0-Inf (AUC0-inf) of 163.3 ± 38.3 ng/mL, 1.2 ± 0.3 h, 729.4 ± 118.3 ng*h/ml and 868.9 ± 117.1 ng*h/ml (means ± S.E.M.), respectively.","Pharmacological profiling of JME-173, a novel mexiletine derivative combining dual anti-inflammatory/anti-spasmodic functions and limited action in Na+ channels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32750364/),[h·ng] / [ml],868.9,161842,DB00379,Mexiletine
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162611,DB00379,Mexiletine
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162612,DB00379,Mexiletine
,8068867,CLH,An increase to 72 +/- 25 mL min-1 in the CLH of cortisol to 6 beta-hydroxycortisol was calculated following rifampicin treatment.,Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],72,162613,DB00379,Mexiletine
,6540110,relative bioavailability,The relative bioavailability was 83.2 +/- 8.9% (mean +/- S.E.).,Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540110/),%,83.2,162876,DB00379,Mexiletine
,6540110,Elimination half-life,"Elimination half-life, volume of distribution and plasma clearance were 10.54 +/- 0.26 h, 2.10 +/- 0.49 l/kg, 6.01 +/- 0.63 ml/min/kg, respectively.",Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540110/),h,10.54,162877,DB00379,Mexiletine
,6540110,volume of distribution,"Elimination half-life, volume of distribution and plasma clearance were 10.54 +/- 0.26 h, 2.10 +/- 0.49 l/kg, 6.01 +/- 0.63 ml/min/kg, respectively.",Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540110/),[l] / [kg],2.10,162878,DB00379,Mexiletine
,6540110,plasma clearance,"Elimination half-life, volume of distribution and plasma clearance were 10.54 +/- 0.26 h, 2.10 +/- 0.49 l/kg, 6.01 +/- 0.63 ml/min/kg, respectively.",Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540110/),[ml] / [kg·min],6.01,162879,DB00379,Mexiletine
,6540110,steady state of,The steady state of plasma mexiletine level was reached 4-5 days after 450 mg/day dosings and ranged 0.75-2.18 micrograms/ml.,Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540110/),[μg] / [ml],0.75-2.18,162880,DB00379,Mexiletine
,3718807,R/S ratios,"The mean R/S ratios for unchanged mexiletine in serum and in urine were 0.78 +/- 0.12 (s.d.) and 0.80 +/- 0.21, respectively.",Stereoselective disposition of mexiletine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718807/),,0.78,163585,DB00379,Mexiletine
,3718807,R/S ratios,"The mean R/S ratios for unchanged mexiletine in serum and in urine were 0.78 +/- 0.12 (s.d.) and 0.80 +/- 0.21, respectively.",Stereoselective disposition of mexiletine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718807/),,0.80,163586,DB00379,Mexiletine
,3718807,R/S enantiomeric ratio,Urinary excretion of mexiletine conjugates consisted mainly of the R-(-)-enantiomer; the mean R/S enantiomeric ratio over 48 h was 9.65 +/- 3.10.,Stereoselective disposition of mexiletine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718807/),,9.65,163587,DB00379,Mexiletine
,3718807,AUC ratio,The mean R/S AUC ratio was 2.94 +/- 0.48 and the renal clearance of the R-(-)-enantiomer was significantly higher (P less than 0.02) than that of the S-(+)-enantiomer.,Stereoselective disposition of mexiletine in man. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718807/),,2.94,163588,DB00379,Mexiletine
,4006364,elimination t1/2,The elimination t1/2 was 18.9 +/- 7.4 hours and oral clearance was 378 +/- 109 ml/min (means +/- SD).,Pharmacokinetics and nondialyzability of mexiletine in renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006364/),h,18.9,166401,DB00379,Mexiletine
,4006364,oral clearance,The elimination t1/2 was 18.9 +/- 7.4 hours and oral clearance was 378 +/- 109 ml/min (means +/- SD).,Pharmacokinetics and nondialyzability of mexiletine in renal failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006364/),[ml] / [min],378,166402,DB00379,Mexiletine
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB00379,Mexiletine
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB00379,Mexiletine
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB00379,Mexiletine
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB00379,Mexiletine
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB00379,Mexiletine
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB00379,Mexiletine
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB00379,Mexiletine
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB00379,Mexiletine
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB00379,Mexiletine
,6199590,terminal half-life,"The decline of MEX in plasma was three-exponential, with a terminal half-life of 14.7 +/- 3.4 (mean +/- SE) h in study I and 11.3 +/- 2.4 h (p less than 0.05) in study II, in the seven patients studied in both phases.",Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199590/),h,14.7,170012,DB00379,Mexiletine
,6199590,terminal half-life,"The decline of MEX in plasma was three-exponential, with a terminal half-life of 14.7 +/- 3.4 (mean +/- SE) h in study I and 11.3 +/- 2.4 h (p less than 0.05) in study II, in the seven patients studied in both phases.",Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199590/),h,11.3,170013,DB00379,Mexiletine
,6199590,steady-state volume of distribution,The steady-state volume of distribution averaged 578 +/- 97 L in study I and 415 +/- 33 L in study II (p less than 0.05).,Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199590/),l,578,170014,DB00379,Mexiletine
,6199590,steady-state volume of distribution,The steady-state volume of distribution averaged 578 +/- 97 L in study I and 415 +/- 33 L in study II (p less than 0.05).,Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199590/),l,415,170015,DB00379,Mexiletine
,6199590,plasma protein binding,"The total plasma clearance, renal clearance, and recovery of MEX in urine were similar in the two studies, as was the plasma protein binding of MEX (64 +/- 2 vs. 57 +/- 3%, NS).",Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199590/),%,64,170016,DB00379,Mexiletine
,6199590,plasma protein binding,"The total plasma clearance, renal clearance, and recovery of MEX in urine were similar in the two studies, as was the plasma protein binding of MEX (64 +/- 2 vs. 57 +/- 3%, NS).",Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199590/),%,57,170017,DB00379,Mexiletine
,3759283,At steady-state plasma concentrations,"At steady-state plasma concentrations were 0.121 +/- 0.033 microgram-ml in the young volunteers, and 0.135 +/- 0.150 microgram/ml in the older subjects.",Effects of age on the pharmacokinetics of mexiletine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759283/),μgram-ml,0.121,173685,DB00379,Mexiletine
,3759283,At steady-state plasma concentrations,"At steady-state plasma concentrations were 0.121 +/- 0.033 microgram-ml in the young volunteers, and 0.135 +/- 0.150 microgram/ml in the older subjects.",Effects of age on the pharmacokinetics of mexiletine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759283/),[μg] / [ml],0.135,173686,DB00379,Mexiletine
,3759283,elimination t 1/2,The elimination t 1/2 was 11.4 +/- 1.78 h in the young subjects and 10.48 +/- 3.06 h in the elderly.,Effects of age on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759283/),h,11.4,173687,DB00379,Mexiletine
,3759283,elimination t 1/2,The elimination t 1/2 was 11.4 +/- 1.78 h in the young subjects and 10.48 +/- 3.06 h in the elderly.,Effects of age on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759283/),h,10.48,173688,DB00379,Mexiletine
,8436157,total area under the curve (AUC),"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),[h·μg] / [ml],15.7,183186,DB00379,Mexiletine
,8436157,total area under the curve (AUC),"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),[h·μg] / [ml],8.16,183187,DB00379,Mexiletine
,8436157,elimination half-lives,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),h,18.5,183188,DB00379,Mexiletine
,8436157,elimination half-lives,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),h,11.6,183189,DB00379,Mexiletine
,8436157,elimination half-lives,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),h,19.2,183190,DB00379,Mexiletine
,8436157,elimination half-lives,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),h,11.7,183191,DB00379,Mexiletine
,8436157,total clearance,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),[ml] / [min],216,183192,DB00379,Mexiletine
,8436157,total clearance,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),[ml] / [min],450,183193,DB00379,Mexiletine
,21157099,detection limit,The detection limit of MEX was 0.008 µg ml(-1) (S/N = 3).,Column-switching HPLC determination of mexiletine using tris(bipyridine)ruthenium(III) electrogenerated chemiluminescence and precolumn derivatization with divinylsulfone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21157099/),[μg] / [ml],0.008,185695,DB00379,Mexiletine
,21157099,S/N,The detection limit of MEX was 0.008 µg ml(-1) (S/N = 3).,Column-switching HPLC determination of mexiletine using tris(bipyridine)ruthenium(III) electrogenerated chemiluminescence and precolumn derivatization with divinylsulfone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21157099/),,3,185696,DB00379,Mexiletine
,2097598,metabolic ratio (Rm),Mean metabolic ratio (Rm) was 0.54 and 0.18 respectively.,"Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097598/),,0.54,189889,DB00379,Mexiletine
,2097598,metabolic ratio (Rm),Mean metabolic ratio (Rm) was 0.54 and 0.18 respectively.,"Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097598/),,0.18,189890,DB00379,Mexiletine
,2097598,Peak serum concentrations (Cmax),"Peak serum concentrations (Cmax) for mexiletine (0.686 +/- 0.110 micrograms/ml), hydroxymethylmexiletine (0.507 +/- 0.087 micrograms/ml), and p-hydroxymexiletine (0.096 +/- 0.046 micrograms/ml) occurred after 3.0, 4.0 and 4.2 +/- 0.6 h.","Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097598/),[μg] / [ml],0.686,189891,DB00379,Mexiletine
,2097598,Peak serum concentrations (Cmax),"Peak serum concentrations (Cmax) for mexiletine (0.686 +/- 0.110 micrograms/ml), hydroxymethylmexiletine (0.507 +/- 0.087 micrograms/ml), and p-hydroxymexiletine (0.096 +/- 0.046 micrograms/ml) occurred after 3.0, 4.0 and 4.2 +/- 0.6 h.","Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097598/),[μg] / [ml],0.507,189892,DB00379,Mexiletine
,2097598,Peak serum concentrations (Cmax),"Peak serum concentrations (Cmax) for mexiletine (0.686 +/- 0.110 micrograms/ml), hydroxymethylmexiletine (0.507 +/- 0.087 micrograms/ml), and p-hydroxymexiletine (0.096 +/- 0.046 micrograms/ml) occurred after 3.0, 4.0 and 4.2 +/- 0.6 h.","Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097598/),[μg] / [ml],0.096,189893,DB00379,Mexiletine
,2097598,volume of distribution (V lambda),"Disposition parameters for mexiletine were as follows: volume of distribution (V lambda), 5.44 +/- 1.44 l/kg; serum clearance (CL) 8.08 +/- 1.23 ml/min/kg.","Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097598/),[l] / [kg],5.44,189894,DB00379,Mexiletine
,2097598,serum clearance (CL),"Disposition parameters for mexiletine were as follows: volume of distribution (V lambda), 5.44 +/- 1.44 l/kg; serum clearance (CL) 8.08 +/- 1.23 ml/min/kg.","Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097598/),[ml] / [kg·min],8.08,189895,DB00379,Mexiletine
,18973279,Quantification limits,Quantification limits were 0.5 ng ml(-1) for the MEX and 0.2 ng ml(-1) for the HMM and PHM enantiomers.,Enantioselective determination of mexiletine and its metabolites p-hydroxymexiletine and hydroxymethylmexiletine in rat plasma by normal-phase liquid chromatography-tandem mass spectrometry: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18973279/),[ng] / [ml],0.5,196930,DB00379,Mexiletine
,18973279,Quantification limits,Quantification limits were 0.5 ng ml(-1) for the MEX and 0.2 ng ml(-1) for the HMM and PHM enantiomers.,Enantioselective determination of mexiletine and its metabolites p-hydroxymexiletine and hydroxymethylmexiletine in rat plasma by normal-phase liquid chromatography-tandem mass spectrometry: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18973279/),[ng] / [ml],0.2,196931,DB00379,Mexiletine
,17142985,Retention times,"Retention times of the BPHP and IS derivatives were 7.7 and 11.5 min, respectively.","Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17142985/),min,7.7,199818,DB00379,Mexiletine
,17142985,Retention times,"Retention times of the BPHP and IS derivatives were 7.7 and 11.5 min, respectively.","Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17142985/),min,11.5,199819,DB00379,Mexiletine
,17142985,detection limit,The regression equation for BPHP showed good linearity in the range of 0.01-1 mg/ml with the detection limit of 0.003 microg/ml.,"Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17142985/),[μg] / [ml],0.003,199820,DB00379,Mexiletine
,2723119,rate of absorption,The rate of absorption of the drug from the gastrointestinal tract was significantly slower in the elderly (1.37 +/- 0.51 hr-1) than in the young group (2.25 +/- 0.79 hr-1).,Pharmacokinetics of mexiletine in the elderly. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723119/),1/[h],1.37,200062,DB00379,Mexiletine
,2723119,rate of absorption,The rate of absorption of the drug from the gastrointestinal tract was significantly slower in the elderly (1.37 +/- 0.51 hr-1) than in the young group (2.25 +/- 0.79 hr-1).,Pharmacokinetics of mexiletine in the elderly. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723119/),1/[h],2.25,200063,DB00379,Mexiletine
,2723119,elimination half-life,The mean values for elimination half-life and oral clearance were 12.3 +/- 3.7 hr and 10.3 +/- 5.4 mL/min/kg respectively in the young group and 14.4 +/- 4.5 hr and 8.5 +/- 2.9 mL/min/kg respectively in the elderly group.,Pharmacokinetics of mexiletine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723119/),h,12.3,200064,DB00379,Mexiletine
,2723119,elimination half-life,The mean values for elimination half-life and oral clearance were 12.3 +/- 3.7 hr and 10.3 +/- 5.4 mL/min/kg respectively in the young group and 14.4 +/- 4.5 hr and 8.5 +/- 2.9 mL/min/kg respectively in the elderly group.,Pharmacokinetics of mexiletine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723119/),h,14.4,200065,DB00379,Mexiletine
,2723119,oral clearance,The mean values for elimination half-life and oral clearance were 12.3 +/- 3.7 hr and 10.3 +/- 5.4 mL/min/kg respectively in the young group and 14.4 +/- 4.5 hr and 8.5 +/- 2.9 mL/min/kg respectively in the elderly group.,Pharmacokinetics of mexiletine in the elderly. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723119/),[ml] / [kg·min],10.3,200066,DB00379,Mexiletine
,2723119,oral clearance,The mean values for elimination half-life and oral clearance were 12.3 +/- 3.7 hr and 10.3 +/- 5.4 mL/min/kg respectively in the young group and 14.4 +/- 4.5 hr and 8.5 +/- 2.9 mL/min/kg respectively in the elderly group.,Pharmacokinetics of mexiletine in the elderly. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723119/),[ml] / [kg·min],8.5,200067,DB00379,Mexiletine
,3671458,recovery,The recovery by this procedure was 83.6%.,Selective solid-phase extraction of mexiletine from human serum prior to its GLC analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3671458/),%,83.6,205678,DB00379,Mexiletine
,15385831,clearances,"On the other hand, ciprofloxacin administration only marginally decreased R-(-)- and S-(+)-mexiletine clearances (2 to 5 L/h; P < 0.05) secondary to a decrease in mexiletine nonrenal clearance.",Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385831/),[l] / [h],2 to 5,220254,DB00379,Mexiletine
,1941626,total clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],621,226923,DB00379,Mexiletine
,1941626,total clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],471,226924,DB00379,Mexiletine
,1941626,nonrenal clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],583,226925,DB00379,Mexiletine
,1941626,nonrenal clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],404,226926,DB00379,Mexiletine
,1941626,elimination half-life,"Moreover, quinidine increased mexiletine elimination half-life in EM from 9 +/- 1 to 11 +/- 2 h (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),h,9,226927,DB00379,Mexiletine
,1941626,elimination half-life,"Moreover, quinidine increased mexiletine elimination half-life in EM from 9 +/- 1 to 11 +/- 2 h (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),h,11,226928,DB00379,Mexiletine
,2189614,bioavailability,Pharmacokinetic studies have shown that oral absorption is rapid with bioavailability of 80-90%.,Mexiletine: pharmacology and therapeutic use. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189614/),%,80-90,228858,DB00379,Mexiletine
,2189614,elimination half-life,Mexiletine is predominantly metabolized by the liver with elimination half-life of 9 to 12 hours.,Mexiletine: pharmacology and therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189614/),h,9 to 12,228859,DB00379,Mexiletine
,6662176,peak plasma concentrations,"The peak plasma concentrations of mexiletine were 0.65 +/- 0.05 (SEM) microgram ml and 1.08 +/- 0.11 micrograms/ml (p less than 0.05) in Studies I and II, respectively.",Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),ml·μg,0.65,236634,DB00379,Mexiletine
,6662176,peak plasma concentrations,"The peak plasma concentrations of mexiletine were 0.65 +/- 0.05 (SEM) microgram ml and 1.08 +/- 0.11 micrograms/ml (p less than 0.05) in Studies I and II, respectively.",Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),[μg] / [ml],1.08,236635,DB00379,Mexiletine
,6662176,peak times,The corresponding peak times were 4.68 +/- 2.04 h and 1.46 +/- 0.17 h (N.S.).,Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),h,4.68,236636,DB00379,Mexiletine
,6662176,peak times,The corresponding peak times were 4.68 +/- 2.04 h and 1.46 +/- 0.17 h (N.S.).,Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),h,1.46,236637,DB00379,Mexiletine
,6662176,lag time,The lag time averaged 0.48 +/- 0.08 h in Study I and 0.39 +/- 0.05 h in Study II (N.S.).,Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),h,0.48,236638,DB00379,Mexiletine
,6662176,lag time,The lag time averaged 0.48 +/- 0.08 h in Study I and 0.39 +/- 0.05 h in Study II (N.S.).,Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),h,0.39,236639,DB00379,Mexiletine
,6662176,elimination half-life,"The elimination half-life was 15.03 +/- 0.61 h and 11.75 +/- 0.80 h (p less than 0.01) in Studies I and II, respectively.",Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),h,15.03,236640,DB00379,Mexiletine
,6662176,elimination half-life,"The elimination half-life was 15.03 +/- 0.61 h and 11.75 +/- 0.80 h (p less than 0.01) in Studies I and II, respectively.",Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),h,11.75,236641,DB00379,Mexiletine
,6662176,plasma protein binding,The plasma protein binding of mexiletine was similar in Studies I and II (61 +/- 2% and 63 +/- 3%; N.S.).,Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),%,61,236642,DB00379,Mexiletine
,6662176,plasma protein binding,The plasma protein binding of mexiletine was similar in Studies I and II (61 +/- 2% and 63 +/- 3%; N.S.).,Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662176/),%,63,236643,DB00379,Mexiletine
,7741779,areas under the curve,"For the areas under the curve, values around 4000 h x ng/ml were found; the plasma half-life of the test preparation was 7.55, for the reference preparation 7.75 h.",[The pharmacokinetics and bioavailability of a new mexiletine preparation in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741779/),[h·ng] / [ml],4000,238190,DB00379,Mexiletine
,7741779,plasma half-life,"For the areas under the curve, values around 4000 h x ng/ml were found; the plasma half-life of the test preparation was 7.55, for the reference preparation 7.75 h.",[The pharmacokinetics and bioavailability of a new mexiletine preparation in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741779/),h,7.55,238191,DB00379,Mexiletine
,7741779,plasma half-life,"For the areas under the curve, values around 4000 h x ng/ml were found; the plasma half-life of the test preparation was 7.55, for the reference preparation 7.75 h.",[The pharmacokinetics and bioavailability of a new mexiletine preparation in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741779/),h,7.75,238192,DB00379,Mexiletine
,2818679,terminal half-life t1/2,The terminal half-life t1/2 MEX was longer in phase I than in phase II (28.4 +/- 12.1 h (betaI) versus 14.06 +/- 4.47 h (II); p less than 0.01).,Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2818679/),h,28.4,242806,DB00379,Mexiletine
,2818679,terminal half-life t1/2,The terminal half-life t1/2 MEX was longer in phase I than in phase II (28.4 +/- 12.1 h (betaI) versus 14.06 +/- 4.47 h (II); p less than 0.01).,Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2818679/),h,14.06,242807,DB00379,Mexiletine
,2818679,total plasma clearance Cl,This prolonged t1/2 MEX was probably due to a decrease of total plasma clearance Cl MEX (3.723 +/- 1.534 ml.kg-1min-1 (I) versus 5.031 +/- 1.28 ml.kg-1min-1 (II).,Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2818679/),[ml] / [kg],3.723,242808,DB00379,Mexiletine
,2818679,total plasma clearance Cl,This prolonged t1/2 MEX was probably due to a decrease of total plasma clearance Cl MEX (3.723 +/- 1.534 ml.kg-1min-1 (I) versus 5.031 +/- 1.28 ml.kg-1min-1 (II).,Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2818679/),[ml] / [kg],5.031,242809,DB00379,Mexiletine
,12830720,lowest detectable concentration,The lowest detectable concentration of this method was 5 micrograms.L-1 (S/N > or = 4).,[HPLC-fluorescent spectrometric determination of serum mexiletine concentration after derivatization with fluram]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830720/),[μg] / [l],5,245929,DB00379,Mexiletine
>,12830720,S/N,The lowest detectable concentration of this method was 5 micrograms.L-1 (S/N > or = 4).,[HPLC-fluorescent spectrometric determination of serum mexiletine concentration after derivatization with fluram]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830720/),,4,245930,DB00379,Mexiletine
,9496401,AUCs,"The mean AUCs after administration of mexiletine alone and in combination with omeprazole 40 mg/d were 6.26 and 6.20 ng.h/L, respectively.",Lack of pharmacokinetic interaction between mexiletine and omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496401/),[h·ng] / [l],6.26,254935,DB00379,Mexiletine
,9496401,AUCs,"The mean AUCs after administration of mexiletine alone and in combination with omeprazole 40 mg/d were 6.26 and 6.20 ng.h/L, respectively.",Lack of pharmacokinetic interaction between mexiletine and omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496401/),[h·ng] / [l],6.20,254936,DB00379,Mexiletine
,16506267,detection limit,The regression equation for CPHP showed a good linearity in the range of 0.03-1 microg/mL with a detection limit of 0.008 microg/mL.,"Sensitive determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, in a rat biological sample by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506267/),[μg] / [ml],0.008,255367,DB00379,Mexiletine
,6668966,mean-transit-time,"The mean-transit-time, T DISSOLVED-IN VITRO, for the hospital-modified capsules (2.8 min) was longer than that of the Mexitil capsule (2.0 min) in 0.1 HCl.",The dissolution and oral bioavailability of mexiletine capsules modified for clinical trial. A preliminary report. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668966/),min,2.8,258401,DB00379,Mexiletine
,6668966,mean-transit-time,"The mean-transit-time, T DISSOLVED-IN VITRO, for the hospital-modified capsules (2.8 min) was longer than that of the Mexitil capsule (2.0 min) in 0.1 HCl.",The dissolution and oral bioavailability of mexiletine capsules modified for clinical trial. A preliminary report. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668966/),min,2.0,258402,DB00379,Mexiletine
,6668966,MATp.o.,This delay in dissolution was complemented by an increase in MATp.o. (0.43 and 0.58 hr respectively for Mexitil and hospital-modified capsules) obtained in one subject.,The dissolution and oral bioavailability of mexiletine capsules modified for clinical trial. A preliminary report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668966/),h,0.43,258403,DB00379,Mexiletine
,6668966,MATp.o.,This delay in dissolution was complemented by an increase in MATp.o. (0.43 and 0.58 hr respectively for Mexitil and hospital-modified capsules) obtained in one subject.,The dissolution and oral bioavailability of mexiletine capsules modified for clinical trial. A preliminary report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668966/),h,0.58,258404,DB00379,Mexiletine
,17766197,t1/2,"The t1/2 values of the three drugs in rats were found to be 5.38+/-0.61, 4.49+/-0.53, and 3.70+/-0.19 h for MXL, MTX, and MTR, respectively.","Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17766197/),h,5.38,273966,DB00379,Mexiletine
,17766197,t1/2,"The t1/2 values of the three drugs in rats were found to be 5.38+/-0.61, 4.49+/-0.53, and 3.70+/-0.19 h for MXL, MTX, and MTR, respectively.","Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17766197/),h,4.49,273967,DB00379,Mexiletine
,17766197,t1/2,"The t1/2 values of the three drugs in rats were found to be 5.38+/-0.61, 4.49+/-0.53, and 3.70+/-0.19 h for MXL, MTX, and MTR, respectively.","Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17766197/),h,3.70,273968,DB00379,Mexiletine
